Graft Versus Host Disease Market Set to Expand at 8.2% CAGR Through 2034, Driven by a Robust Pipeline | DelveInsight

The 7MM GvHD market has demonstrated substantial growth in recent years, fueled by rising transplant rates, an aging population, and the introduction of innovative therapies from key pharmaceutical companies, including ICSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech, Ironwood, Medac, and others.
DelveInsight's "Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides an in-depth understanding of Graft Versus Host Disease (GvHD), historical and forecasted epidemiology, as well as the GvHD market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The GvHD market forecast anticipates a CAGR of 8.2% through 2034 from USD 1.3 billion in 2023. Regionally, the United States represents around 70% of the GvHD market, thanks to favorable reimbursement policies and rapid adoption of new, premium-priced therapies. The EU4 and the UK together account for about 19% of the GvHD market.

Download the GvHD market report to understand which factors are driving the Graft Versus Host Disease therapeutic market @ Graft Versus Host Disease Market Trends [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The report also analyzes historical and projected GvHD epidemiology, segmented by total allogenic transplant cases, total Graft Versus Host Disease prevalence, type-specific cases of Graft Versus Host Disease, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, total treated cases of Graft Versus Host Disease, and mortality adjusted treated cases of Graft Versus Host Disease.

DelveInsight estimates approximately 52K Graft Versus Host Disease cases in the 7MM. In 2023, the EU4 and the UK recorded the highest incidence of Grade D[IV] Graft-Versus-Host Disease, aligning with patterns observed in hematologic malignancy transplants.

Discover evolving trends in Graft Versus Host Disease patient pool forecasts @ Graft Versus Host Disease Epidemiology Analysis [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The Graft Versus Host Disease Treatment Market Report provides insights into current GvHD treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM GvHD market size from 2025 to 2034. Current GvHD therapies include steroids, NIKTIMVO, JAKAFI, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, among others.

Graft Versus Host Disease Treatment is evolving from broad immunosuppression to targeted and cell-based therapies. JAKAFI (ruxolitinib), a JAK1/JAK2 inhibitor, is a cornerstone of GvHD treatment and generates substantial revenue due to its proven efficacy in steroid-refractory cases.

DelveInsight's analysis indicates that the GvHD clinical trials market is highly active, with numerous investigational therapies in various stages of development. Notable candidates include ZEMAIRA (CSL Behring), EQ001 (Equillium/Biocon), MaaT013 (MaaT Pharma), RGI-2001 (REGiMMUNE), MC0518 (Medac), RLS-0071 (ReAlta Life Sciences), VIMSELTINIB (Deciphera Pharmaceuticals), ARSCIMED (Medsenic/BioSenic), ASC-930 (ASC Therapeutics), CYP-001 (Cynata Therapeutics), F-652 (Yifan Pharmaceutical), and APRAGLUTIDE (Ironwood), among others.

Unlock which emerging Graft Versus Host Disease drug is expected to capture the largest market share in 7MM by 2034. Visit the Graft Versus Host Disease Market Insights [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

In January 2025, the FDA approved Incyte's and Syndax's Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for the treatment of chronic graft-versus-host disease (GVHD) in adults and pediatric patients based on data from the AGAVE-201 trial. This demonstrates encouraging progress in the graft versus host disease clinical trials market.

Furthermore, in March 2025, Signal12 Pharmaceuticals secured FDA alignment for their Phase 3 trial of Pro-ocular, a novel drop-free therapy for ocular graft-versus-host disease, following successful Phase 2 results showing sustained improvements in corneal staining and symptom scores. These recent developments indicate a positive momentum in the GvHD treatment market.

Upcoming milestones may include potential label expansions of cellular therapies like mesenchymal stromal cells, which could redefine first-line treatment strategies. However, challenges remain, such as standardizing response criteria across clinical trials and addressing the financial strain associated with chronic graft versus host disease treatment. DelveInsight's report emphasizes that overcoming these challenges will require collaboration among pharmaceutical stakeholders and transplant networks to optimize patient stratification and track outcomes effectively.

Table of Contents

1. Key Insights

2. Report Introduction

3. GvHD Market Overview at a Glance

4. Executive Summary

5. Key Events

6. GvHD Background and Overview

7. Methodology

8. GvHD Epidemiology and Patient Population

9. GvHDPatient Journey

10. GvHD Marketed Drugs

11. GvHD Emerging Drugs

12. GvHD - 7MM Market Analysis

13. KOL Views

14. GvHD Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Related Reports

Graft versus host disease (GvHD) Pipeline Insight [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Graft versus host disease Pipeline Insight provides comprehensive insights about the GvHD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, and Amgen among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graft-versus-host-disease-market-set-to-expand-at-82-cagr-through-2034-driven-by-a-robust-pipeline-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.